Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above Two Hundred Day Moving Average - Time to Sell?

Key Points

• Cumberland Pharmaceuticals shares crossed above their 200-day moving average, reaching $8.50 before closing at $6.69; the 200-day average was $5.27.
• Analyst sentiment remains negative: Wall Street Zen downgraded the stock to “hold,” Weiss Ratings reiterated a “sell (D-)” rating, and MarketBeat reports a consensus “Sell” rating.
• The company reported a quarterly loss of $0.20 per share, missing estimates by $0.07, while revenue of $0.17 million fell far short of the $8.50 million consensus forecast; net margin and return on equity were also negative.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.27 and traded as high as $8.50. Cumberland Pharmaceuticals shares last traded at $6.69, with a volume of 190,588 shares changing hands.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Wall Street Zen cut shares of Cumberland Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cumberland Pharmaceuticals in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cumberland Pharmaceuticals has a consensus rating of "Sell".

Cumberland Pharmaceuticals Stock Performance

The firm's 50-day moving average price is $7.18 and its 200 day moving average price is $5.27. The company has a market cap of $100.22 million, a price-to-earnings ratio of -9.42 and a beta of 0.08.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.07). Cumberland Pharmaceuticals had a negative net margin of 34.40% and a negative return on equity of 28.81%. The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $8.50 million.

Cumberland Pharmaceuticals Announces Dividend

The business also recently declared a dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, July 23rd were paid a $1.50 dividend.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC bought a new position in Cumberland Pharmaceuticals during the fourth quarter worth about $1,358,000. BlackRock Inc. bought a new stake in shares of Cumberland Pharmaceuticals in the 2nd quarter valued at about $412,000. Bank of New York Mellon Corp bought a new stake in shares of Cumberland Pharmaceuticals in the 2nd quarter valued at about $379,000. Marshall Wace LLP bought a new stake in shares of Cumberland Pharmaceuticals in the 4th quarter valued at about $192,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Cumberland Pharmaceuticals by 11.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company's stock valued at $876,000 after acquiring an additional 27,980 shares during the period. Institutional investors own 15.51% of the company's stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc NASDAQ: CPIX is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland's strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company's flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source